Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 5 days | $ 1,149.00 |
Description | Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy. |
Synonyms | AF-102B, FKS 508, SNI 2011, HSDB 7286 |
Molecular Weight | 199.31 |
Formula | C10H17NOS |
CAS No. | 107233-08-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cevimeline 107233-08-9 AF-102B SNI-2011 FKS508 SNI2011 FKS-508 FKS 508 HSDB7286 SNI 2011 HSDB-7286 HSDB 7286 inhibitor inhibit